Sanofi leader urges Australia to look beyond the laboratory in building vaccine capability

Term limits are an accepted and expected part of sporting organisations, ASX-listed companies, and bureaucracy because they enable fresh thinking and reduce the risk of institutional capture. What is so special about these entities that terms of more than 10 or 15 years are considered acceptable and even normal?

MSD Managing Director Chifumi Umeda made the point during a media conference with Health Minister Mark Butler, describing the outcome as the end of a "long and winding road".

Astellas Australia has appointed Guillaume Pfeiffer as its new general manager, bringing more than two decades of experience across specialty medicines, rare diseases, oncology and advanced therapies to the local business.

Dr Nic Horridge, General Manager, Roche Pharmaceuticals Australia, said the PBS listing of GAZYVA is an “important milestone in a disease area of high unmet need”.

The Pharmaceutical Benefits Advisory Committee will consider new medicine listings, vaccine funding proposals and broader PBS reforms at its September 2026 intracycle meeting.

Across 15 categories, the winners included clinicians, organisations, researchers, advocates and services whose work has made healthcare more accessible, humane and responsive to the people at its centre.

Why pulling the same 'levers' on reform cannot work. Comparing one medicines access program and its humanitarian underpinnings to our institutional frameworks. The need for term limits on advisory committees, the enduring unfairness of medicine co-payments, and the phrase of the week.

Weight loss medicines are emerging as a major sales driver for Australia’s major wholesalers and pharmacy operators, with both Sigma Healthcare and Wesfarmers Health citing strong demand for GLP-1 treatments as a contributor to revenue growth.

Without further action, the Pharmacy Guild says the $25 general co-payment will resume annual indexation from January 1, 2027, putting it on track to reach about $30 by the end of the decade.

Sandoz Australia and New Zealand has been named among Australia’s Top 100 Best Workplaces for 2026, ranking 15th in the medium-sized business category and standing as the only pharmaceutical company included in that division.

Mayne Pharma has emerged from a difficult year with a sharper focus on women’s health, direct-to-patient dispensing, and manufacturing growth, despite lower revenue and earnings.

Olympic champion and Australian icon Cathy Freeman will be the guest of honour at tonight's 2026 Patient’s Choice Awards, a national celebration of the people and organisations helping to make healthcare more compassionate, responsive and centred on the needs of patients.

Chief executive and co-founder Sally Panton said the Mitsubishi partnership was an important vote of confidence in the company’s ambitions to build a regulated cellular-health platform with international reach.

Genetic Signatures and Microba Life Sciences have announced they are in preliminary discussions about a potential merger that would combine rapid infectious disease testing with gut microbiome profiling and create a larger ASX-listed diagnostics business.

Any assessment of Australia’s use of health technology assessment requires an historical lens, at the very least for context, but also for learnings. The system's history makes it predictable. It is how we know what comes next.

Chief executive Jon Pilcher said the approval was especially meaningful given the lack of an approved Rett syndrome treatment in Europe to date.

QIMR Berghofer, one of Australia's leading medical research institutions, has appointed internationally recognised geneticist Professor Brandon Wainwright AM as its next Director and Chief Executive Officer.

Dr Krishan Thiru, Medical Director for Pfizer Australia and New Zealand, said the results provide important local evidence at a time when infants face their greatest risk of severe RSV disease.

The organisation has pointed to the potential impact on cancer treatment and care, highlighting that the policyholders impacted by the reduction are more likely than any other age group to access cancer treatment.

Acrux has appointed physician and biopharmaceutical executive Dr Jolanta Airey as its chief medical officer, strengthening its leadership team as it prepares to advance its female testosterone treatment toward Phase 3 clinical trials in the United States.